Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC). The findings were published in Annals of Oncology on May 13, 2023. Most patients with DTC receive successful treatment.

https://www.miragenews.com/immune-modulator-fails-to-boost-survival-in-1076566/

#miragenews